Toll manufacturing - 4 News by Merck for the biotechnology industry

Toll manufacturing - 4 News by Merck for the biotechnology industry

image description

Merck to Become First Provider to Offer Fully Integrated mRNA Services

New sites at Darmstadt and Hamburg complement Merck’s global integrated mRNA service network

28-Sep-2023 - Merck became the first CTDMO (contract testing, development and manufacturing organization) to offer integrated services for all critical stages of mRNA development, manufacturing, and commercialization, including products and testing. The company opened two new GMP-grade mRNA drug substance ...

toll manufacturing contract development contract services
image description

Merck Completes Acquisition of Exelead and Plans to Invest More Than € 500 Million in Technology Scale-Up

Company now offers comprehensive end-to-end services across mRNA value chain

24-Feb-2022 - Merck announced the closing of the transaction to acquire Exelead, following regulatory clearances and the fulfillment of other customary closing conditions, for approximately USD780million in cash. The business combination is expected to enable Merck’s Life Science business sector to provide ...

toll manufacturing contract development mRNA drugs
image description

Definitive Agreement to Acquire Exelead will Strengthen Merck’s CDMO Offering for mRNA

Targeted acquisition to accelerate novel modalities service offering

07-Jan-2022 - Merck has signed a definitive agreement to acquire Exelead, a biopharmaceutical contract development and manufacturing organization (CDMO), for approximately USD780million in cash. Exelead specializes in complex injectable formulations, including Lipid Nanoparticle (LNP) based drug delivery ...

toll manufacturing contract development drug delivery
image description

Merck Completes New Viral Vector Contract Development Manufacturing Facility for Gene Therapy

Growth through investments in the “Big 3”

13-Oct-2021 - Merck announced the opening of its second Carlsbad, California-based facility, significantly expanding its global CDMO footprint. This new €100 million, 140,000-square foot facility will more than double the company’s existing capacity to support large-scale commercial and industrial ...

toll manufacturing cell therapies contract development

These products might interest you

Custom qPCR and dPCR primers and PCR assay development.

Custom qPCR and dPCR primers and PCR assay development. by Microsynth

Assay Design, Validation and Analysis - Primers and Probes for qPCR and dPCR Applications

High-quality qPCR and dPCR probes, extensive experience in assay design, development and validation

PCR reagents
View product
Show all toll manufacturing
Haven't found the right news yet?

The bionity.com news search

Start your targeted search now with a wide range of filter options. Our database includes an archive of 27,213 life science news from business and science, which you can search by topic and organization, filtered by time and geography.

Start news search now